Digital Health: New Approaches in Hypertension Management

Jamie Kitt1, Rachael Fox2, Katherine L Tucker3*

1Radcliffe Department of Medicine (Cardiovascular Division), University of Oxford, UK
2University of Melbourne, Melbourne, Australia
3Nuffield Department of Primary Care, University of Oxford, UK

Article Info

Article Notes
Received: January 21, 2020
Accepted: February 11, 2020

*Correspondence:
Dr. Katherine Tucker, Nuffield Department of Primary Care, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, OX2 6GG, UK; Telephone No: +44 (0)1865 617852; Email: Katherine.tucker@phc.ox.ac.uk.

© 2020 Tucker KL. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.

Keywords:
Self-monitoring
Hypertension
Smart-phones
Apps
Telemonitoring
Self-management

Abstract

Hypertension is a key risk factor for cardiovascular disease. Globally, approximately a third of people with hypertension remain undiagnosed, and of those diagnosed, about half are not taking antihypertensive medication. The World Health Organization has estimated that globally hypertension directly or indirectly causes the deaths of at least nine million people every year.

There is a trend towards self-monitoring of blood pressure (BP), where patients are empowered to be involved in hypertension screening and diagnosis. Novel technology, including smartphones and Blue-tooth® enabled telemonitoring, are new tools that are likely to be increasingly important in hypertension management. Several studies have shown the benefit of self-monitoring of BP coupled with co-interventions (such as telemonitoring) in improving BP management. However, these new technologies must be properly assessed and clinically validated prior to widespread implementation in the general population, or within special groups. In this mini-review, we examine how technology might improve the detection and management of hypertension.

Introduction

Treating hypertension has been shown to result in marked reductions in the risk of long-term cardiovascular disease1,2. Despite strong evidence for such treatment, it is widely recognised that many people remain un-diagnosed (between a third and a half of patients), indicating the need for better screening3, and 40% of those on hypertensive registries remain sub-optimally controlled4. New approaches, including new technologies, are needed to improve screening, detection and control of raised blood pressure (BP).

The widespread accessibility of smartphones and mobile health applications bring with them a new potential for the ubiquitous monitoring of parameters such as blood pressure. Such technology can be used for self-monitoring, telemonitoring, as part of virtual clinics and/or in artificial intelligence (AI)-assisted management. All of these can be done with a traditional cuff-based monitor (with or without Bluetooth®) or with novel cuffless blood pressure monitoring devices.

A vital issue with both smartphones/tablet apps and novel cuffless devices is the lack of an agreed standard for validating the technology. This is a rapidly expanding field, with > 180 apps now existing relating to blood pressure monitoring. These devices are even foraying into derived measurement. For example, Cardiogram®5 on the Apple® watch has been evaluated for its efficacy at using deep learning algorithms to predict hypertension from inputs of heart rate and step count. However, the involvement
of medical experts in the development process has only taken place in <5% of blood pressure apps. At present, no mobile apps have obtained approval for use as BP measuring/diagnostic devices by the US Food and Drug Administration or European Commission, though clinic validation is now being sought by some manufacturers. As a result, there is currently limited incorporation of this technology into clinical practice.

The two most widely accepted, utilised and promising digital health technologies are self-monitoring and telemonitoring, both of which are explored further below. How these may fit into future models of care for hypertension is summarised in Figure 1.

**Self-Monitoring**

A recent systematic review of blood pressure self-monitoring by Sheppard et al., which included 22 eligible trials and 6,522 participants showed that self-monitoring was associated with an improvement in clinic systolic BP vs. standard care at a 12-month time-point (−3.12 mm Hg, [95% confidence intervals −4.78, −1.46 mm Hg]. This

---

**Figure 1:** How digital technology may fit into future models of care. BP: Blood Pressure; ABPM: Ambulatory Blood Pressure Monitoring; HBPM: Home Blood Pressure Monitoring; PPG: Photoplethysmogram

---

remained true irrespective of the number of hypertension-related co-morbidities. This review also found, that intense interventions [such as those with self-management, tailored education, 1:1 support from a health care professional or pharmacist] were more effective than low-intensity interventions in certain patients. This included those with obesity (P < 0.001 for all outcomes, OR for likelihood of uncontrolled clinic BP at follow up 1.12 [low intensity] v. OR 0.37 [high intensity]). This highlights the importance of co-intervention support for conditions such as these. This effect was not observed in patients with coronary heart disease, diabetes, or chronic kidney disease, potentially due to lack of power, as there was some evidence to suggest that self-monitoring is effective in these patients in combination with high-intensity co-interventions.20

### Telemonitoring

Randomised controlled trials over the past 10-15

<p>| Table 1: A summary of digital technologies alongside some of the key advantages and disadvantages of each. BP: Blood Pressure; HCP: Health Care Professionals; PPG: Photoplethysmogram |</p>
<table>
<thead>
<tr>
<th>Digital Health Technology</th>
<th>Description</th>
<th>Examples</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-screening/monitoring BP cuffs</td>
<td>Patients measure BP outside of physician contacts with validated automatic sphygmomanometers. Can be used for screening, diagnosis or management. Management (termed self-management) is possible by sharing self-monitored readings with HCPs to enable titration of medications.</td>
<td>Home blood pressure monitors or public blood pressure cuffs in settings including pharmacies, work places and grocery stores10-12. May utilise Bluetooth® and smartphone applications for transmission of readings. More effective when combined with co-interventions such as self-management or lifestyle counselling12.</td>
<td>No training required, low cost, patient autonomy, convenient, increased detection of hypertension10-12.</td>
<td>Data privacy concerns, lack of awareness of the technology, lack of education, and 50% of patients do not tell clinicians they are self-monitoring or share the readings in a meaningful manner13.</td>
</tr>
<tr>
<td>Cuff-less ambulatory BP monitoring devices</td>
<td>Wearable devices providing continuous BP monitoring with applications in diagnosis and management. Devices may utilise ECG signals, PPG signals or more commonly a combination of the two to determine BP. Machine learning and neural networks have also been incorporated in some devices14.</td>
<td>Sensors may be embedded in wearable devices including wrist watches, T-shirts, heart rate belts, glasses frames or placed behind the ears14. Data from cuff-less BP monitoring devices may be transmitted to smartphone applications (see telemonitoring below)14.</td>
<td>Continuous monitoring of BP without disruption to daily activities, portable, convenient, discreet14.</td>
<td>Lack of clinical validation and standardisation, variable accuracy of devices14.</td>
</tr>
<tr>
<td>Mobile health (mHealth) and smartphone apps</td>
<td>Potential use for screening, diagnosis and management. Apps record BP readings and may incorporate additional features such as reminder functions, logbooks or information on lifestyle management. Can be used in conjunction with Bluetooth® BP cuffs/cuff-less devices as part of telemonitoring if data export functions are available.</td>
<td>Over 180 apps existing to measure blood pressure6. Examples include AMICOMED® for Android systems and Bloedruk® for iOS devices.</td>
<td>Convenient, accessibility, low cost, patient autonomy, widespread ownership of smartphones6.</td>
<td>Lack of clinical validation and standardisation, majority are of poor quality, inaccuracy, minimal involvement of healthcare agencies in development, data privacy issues, more limited use in elderly populations6,15.</td>
</tr>
<tr>
<td>Telemonitoring</td>
<td>Tele-monitoring is a particular application of telemedicine—the transfer of data remotely—which in this case consists of automatic data transmission of BP readings. This can allow clinicians to titrate medication based on self-monitoring results16,17.</td>
<td>Several systems available; This can be done by text messages, e-mail or apps via a Cloud® upload17. Additional features such as reminders for BP measurement or tools to enhance medication adherence may be included16,17.</td>
<td>No training required, patient autonomy, convenient, increased detection of hypertension, ensures collaboration with treating physician, increased self-awareness of health17.</td>
<td>Improves chances of BP control compared to self-monitoring alone16, has higher costs associated than self-monitoring alone16,17.</td>
</tr>
<tr>
<td>Virtual clinics</td>
<td>Structured online interactions between a patient and health professional to provide follow up for face-to-face visits18,19.</td>
<td>Utilised as follow up to an in-person visit. Patients are given access via an email or link to a secure virtual visit website through which they are directed to enter blood pressure readings, complete set questions or type issues as free text. The clinician reviews this data and responds with management decisions and a plan for follow up18,19.</td>
<td>Reduces number of face-to-face primary care office visits required, convenient, time efficient, no difference in SBP control compared to specialist visits16,19.</td>
<td>Studies limited to patients with reasonably well controlled hypertension, requires access to internet connection and equipped devices18.</td>
</tr>
</tbody>
</table>
years have investigated whether the home blood pressure telemonitoring is associated with improvements in healthcare outcomes. In a large meta-analysis, all studies included demonstrated excellent acceptance of the technology by both doctors and patients, as well as high levels of adherence to telemonitoring programs. Home BP monitoring has in fact, been included in the NICE guidelines for adult hypertension since 2011.

Until recently, the key evidence missing from trials of telemonitoring was whether the use of such data by clinicians actually led to lower blood pressure. In 2018, the TASMINH4 trial randomised primary care physicians to utilising self-monitored BP readings to titrate antihypertensives, with or without telemonitoring vs. relying on standard clinic readings alone. This trial demonstrated better blood pressure control in the arm using self-monitored readings compared to the arm using clinic readings alone. The telemonitoring group also achieved a lower BP more quickly than self-monitoring alone, but overall these readings were not significantly different at the primary end of 12 months.

**Implementation of Novel Digital Health Technology in Special Groups**

**Telemonitoring and heart failure**

Several studies have demonstrated the applicability of remote telemonitoring beyond optimising blood pressure control in patients who often have several other cardiac comorbidities. One randomised, controlled and open-label clinical trial in 40 patients with chronic heart failure in north-western Mexico, demonstrated telemonitoring reduced their weight by an average of 1.4kg (p=0.01 with Mann-Whitney U test), improved symptom control, and lowered their systolic blood pressure (SBP) from 133 ± 19 mmHg to 125 ± 10 mmHg. This translated into a cost of care decrease of more than 50% compared to traditional medical consultation (traditional medical consultation group was observed to have an average cost of $14,185.90 Mexican pesos per patient, in contrast with the telemonitored group, $5543.00 Mexican pesos). Furthermore, admission to the European heart failure self-care behaviour scale of blood pressure, pulse, SpO2 and weight. Changes in the European heart failure self-care behaviour scale questionnaire and EQ-5D-5L quality of life questionnaire revealed a general, positive effect of by increasing self-awareness of participants about their condition.

Several other small studies have been less convincing in demonstrating the benefit of telemonitoring but the results of larger RCTs are anticipated including HeartMan,

and in the UK the SUPPORT-HF 2 study, which should determine if telemonitoring with information technology-supported specialist management is more effective in optimising medical therapy than home monitoring alone for patients with heart failure.

**Telemonitoring in atrial fibrillation**

Hypertension is a risk factor for atrial fibrillation (AF), and approximately 50% of those with AF have hypertension, making blood pressure measurement an important aspect of care in these patients. However, it is widely recognised that there are severe limitations to current methods of BP monitoring in those with AF.

Validation studies of automated blood pressure devices often list AF as an exclusion criteria, resulting in a lack of evidence regarding the accuracy of these devices. This in turn, makes reliable out-of-office BP measurement, including home and ambulatory BP monitoring, more difficult in this population. As a result, NICE and European guidelines currently both recommend manual measurement of blood pressure when AF is present, there may well be a role for novel digital technology in assisting screening and diagnosis of AF itself however, and recent publications such as the APPLE HEART study in NEJM last year as testament to their potential. In this study, more than 419,000 participants were recruited, 2,161 received abnormal notifications from their Apple watch® and only 64% of that 2,161 completed the end of study survey. In those that did receive irregular pulse notifications, the positive predictive value was 0.84 (95% CI, 0.76 to 0.92) for observing atrial fibrillation on the ECG simultaneously with a subsequent irregular pulse notification and 0.71 (97.5% CI, 0.69 to 0.74) for observing atrial fibrillation on the ECG simultaneously with a subsequent irregular tachogram. This study illustrates both the potential benefit and risks of such technology. Digital-tech studies can attract huge patient numbers needed when event rates may be low, but are associated with participant retention and dropout issues as well as issues with reliability and validation of the ‘app’ against current ‘gold standard’ screening/diagnostic methods e.g. in the APPLE HEART study only 450/2161 (21%) actually returned a confirmatory ECG patch sent to them that was of diagnostic quality. This puts participants at risk of an incorrect diagnosis and does not meet current validation method standards.

**Pregnancy**

In the UK, women are empowered to look after their own medical notes throughout pregnancy. As maternity notes move to a digital platform, this offers additional opportunities for digital health technology in this group. In the future, women may be able to feed data into the system (e.g. blood glucose and BP) allowing the above technologies to tie in with electronic records.
Blood pressure monitoring: Self-monitoring of BP in pregnancy has been shown to be feasible with the potential to detect hypertensive disorders sooner than standard care. A recent survey found that many pregnant women are already self-monitoring their BP, although they may not always discuss their readings with health care professionals. Self-monitoring opens up the possibility of re-organising antenatal care and research into the potential for women to monitor their own BP and receive their care in groups is ongoing. Two large trials of BP monitoring have just finished recruiting higher risk and hypertensive women to assess whether self-monitoring improves the detection and/or control of hypertension in pregnancy. (BUMP1 and BUMP2, https://clinicaltrials.gov/ NCT03334149). The results of these trials will make the place of self-monitoring in pregnancy clearer.

Gestational diabetes: Self-monitoring of glucose in gestational diabetes also appears feasible, acceptable and beneficial. In one randomised trial of smart phone app based self-monitoring vs. standard clinical care, participants reported higher satisfaction with care (intervention: median 43, IQR 39-46; control: median 44.5, IQR 41-46, p=0.049), preterm birth occurred less frequently (5/101, 5.0% vs 13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) and there were also fewer caesarean deliveries in the self-monitoring group. The benefits of telemedicine in diabetes in pregnancy are reinforced in a recent systematic review and meta-analysis, which demonstrated a modest but statistically significant improvement in HbA1c associated with the use of a telemedicine technology.

Postpartum monitoring

A recent randomised feasibility trial on self-management of BP following a hypertensive pregnancy demonstrated self-management (where women titrate their own hypertensive medications based on home readings) has the potential to make a significant improvement in BP control during the post-partum period. The trial used a purpose-designed app that allowed women to record self-monitored BP, to receive reminders to monitor their BP, and provided real-time automated medication titration feedback based on NICE guidance at that time. The technology was found to be acceptable, with 85% adherence, accurate, and resulted in a diastolic blood pressure benefit of mean -4.5 mmHg at 6 months' post-partum. A recent qualitative paper based on this work also found that this approach was empowering and valued by the vast majority of participants.

Self and telemonitoring also appear to offer benefits in this group of patients in two other areas of prenatal care based on the current literature: a) cardiotocography; b) prenatal ultrasound. The majority of publications are pilot projects on; remote consultation, education, coaching, screening, monitoring and selective booking. These studies mostly report potential medical and/or economic benefits by mobile health applications over conventional care for very specific situations, indications and locations.

Conclusion

Current research suggests that novel digital health technology might support improved detection and management of hypertension and its related comorbidities. With support, patients can be empowered to be more involved with their health and several studies have shown the benefit of telemonitoring and self-management of hypertension and its associated comorbidities. However, new technologies must be properly assessed and clinically validated prior to implementation and suitable validation processes needed to be agreed. Further research is underway that should improve our understanding of the role of these technologies.

Acknowledgements

KT is currently funded through a National Institute for Health Research (NIHR) programme for applied research (RP-PG-0614-20005). JK is funded through a British Heart Foundation Clinical Research Training Fellowship (BHF Grant number FS/19/7/34148). KT and JK have received funding from the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care Oxford (NIHR CLAHRC Oxford) now recommissioned as NIHR Applied Research Collaboration Oxford and Thames Valley. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

References


